The mandate for creation of a national peripheral arterial disease public awareness program: An opportunity to improve cardiovascular health

Vascular Medicine

Volumn 9, Issue 1, 2004, Pages 78-86

  Hirsch, Alan T ^a   Gloviczki, Peter ^b   Drooz, Alain ^c   Lovell, Marge ^d   Creager, Mark A ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

^c Vascular/Interventional Associates   (United States)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERY DISEASE; AWARENESS; CARDIOVASCULAR SYSTEM; EDUCATION PROGRAM; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH PROMOTION; HEALTH STATUS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NON PROFIT ORGANIZATION; ORGANIZATION; PLANNING; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; UNITED STATES;

EID: 3042731868     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x04vm527xx     Document Type: Review

References (37)

1. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71: 510-15.
2. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly. The Rotterdam Study. Arterioscler Thromb Vasc Biol 1998; 18: 185-92.
3. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384-92.
4. Leng GC, Lee AJ, Fowkes FG et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996; 25: 1172-81.
5. Kornitzer M, Dramaix M, Sobolski J, Degre S, De Backer G. Ankle/arm pressure index in asymptomatic middle-aged males: an independent predictor of ten-year coronary heart disease mortality. Angiology 1995; 46: 211-19.
6. Zheng ZJ, Sharrett AR, Chambless LE et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 1997; 131: 115-25.
7. Newman AB, Sutton-Tyrrell K, Vogt MT, Kuller LH. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA 1993; 270: 487-89.
8. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-86.
9. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation 1990; 82: 1925-31.
10. Vogt MT, Cauley JA, Newman AB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993; 270: 465-69.
11. Breek JC, Hamming JF, De Vries J, van Berge Henegouwen DP, van Heck GL. The impact of walking impairment, cardiovascular risk factors, and comorbidity on quality of life in patients with intermittent claudication. J Vasc Surg 2002; 36: 94-99.
12. Treat-Jacobson DT, Halverson SL, Ratchford A, Regensteiner JG, Lindquist R, Hirsch AT. A patient-derived perspective of health-related quality-of-life in peripheral arterial disease. J Nurs Scholarsh 2002; 34: 55-60.
13. Khaira HS, Hanger R, Shearman CP. Quality of life in patients with intermittent claudication. Eur J Vasc Endovasc Surg 1996; 11: 65-69.
14. Vogt MT, Cauley JA, Kuller LH, Nevitt MC. Functional status and mobility among elderly women with lower extremity arterial disease: the Study of Osteoporotic Fractures. J Am Geriatr Soc 1994; 42: 923-29.
15. Barletta G, Perna S, Sabba C, Catalano A, O'Boyle C, Brevetti G. Quality of life in patients with intermittent claudication: relationship with laboratory exercise performance. Vasc Med 1996; 1: 3-7.
16. Pell JP for the Scottish Vascular Audit Group. Impact of intermittent claudication on quality of life. Eur J Vasc Endovasc Surg 1995; 9: 469-72.
17. Ponte E, Cattinelli S. Quality of life in a group of patients with intermittent claudication. Angiology 1996; 47: 247-51.
18. McDermott MM, Mehta S, Greenland P. Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med 1999; 159: 387-92.
19. McDermott MM, Mehta S, Liu K et al. Leg symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease. J Gen Intern Med 1999; 14: 173-81.
20. McDermott MM, Fried L, Simonsick E, Ling S, Guralnik JM. Asymptomatic peripheral arterial disease is independently associated with impaired lower extremity functioning: the Women's Health and Aging Study. Circulation 2000; 101: 1007-12.
21. McDermott MM, Greenland P, Liu K et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001; 286: 1599-606.
22. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000; 31 (1 pt 2): S1-S296.
23. Belch JJF, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003; 163: 884-92.
24. Hirsch AT, Halverson SL, Treat-Jacobson D et al. The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care. Vasc Med 2001; 6: 87-96.
25. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-24.
26. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-21.
27. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
28. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53. [Errata, N Engl J Med 2000; 342: 748, 1376.]
29. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
30. Burt VL, Cutler JA, Higgins M et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26: 60-69.
31. Chobanian AV, Bakris GL, Black HR et al and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-71.
32. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
33. Pieper RM, Arnett DY, McGovern PG, Shahar E, Blackburn H, Luepker RV. Trends in cholesterol knowledge and screening and hypertension awareness and treatment, 1980-1992. The Minnesota Heart Survey. Arch Intern Med 1997; 157: 2326-32.
34. Farquhar JW, Fortmann SP, Flora JA et al. Effects of communitywide education on cardiovascular disease risk factors. The Stanford Five-City Project. JAMA 1990; 264: 359-65.
35. Frank E, Winkleby MA, Fortmann SP, Rockhill B, Farquhar JW. Improved cholesterol-related knowledge and behavior and plasma cholesterol levels in adults during the 1980s. JAMA 1992; 268: 1566-72.
36. Fortmann SP, Flora JA, Winkleby MA, Schooler C, Taylor CB, Farquhar JW. Community intervention trials: reflections on the Stanford Five City Project experience. Am J Epidemiol 1995; 142: 576-86.
37. NHLBI Workshop on Peripheral Arterial Disease (PAD): developing a public awareness campaign meeting summary. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, 2003: 32 pages.